{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Healthy+Control+Subjects&page=29",
    "query": {
      "condition": "Healthy Control Subjects",
      "page": 29
    },
    "page_size": 10
  },
  "pagination": {
    "page": 29,
    "page_size": 10,
    "total_count": 1099,
    "total_pages": 110,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Healthy+Control+Subjects&page=30&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Healthy+Control+Subjects&page=28&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-11T14:00:04.294Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02325050",
      "title": "A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "MVA-BN-Filo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ad26. ZEBOV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Janssen Vaccines & Prevention B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 164,
      "start_date": "2015-01-08",
      "completion_date": "2017-05-08",
      "has_results": false,
      "last_update_posted_date": "2017-06-14",
      "last_synced_at": "2026-11-11T14:00:04.294Z",
      "location_count": 1,
      "location_summary": "Rockville, Maryland",
      "locations": [
        {
          "city": "Rockville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02325050"
    },
    {
      "nct_id": "NCT02155205",
      "title": "A Thorough QT Study of Telotristat Etiprate",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "QT Interval"
      ],
      "interventions": [
        {
          "name": "Telotristat etiprate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lexicon Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 48,
      "start_date": "2014-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-09-08",
      "last_synced_at": "2026-11-11T14:00:04.294Z",
      "location_count": 1,
      "location_summary": "Evansville, Indiana",
      "locations": [
        {
          "city": "Evansville",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02155205"
    },
    {
      "nct_id": "NCT01264783",
      "title": "Safety and Tolerability of RNS60 Given by IV to Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myocardial Infarct"
      ],
      "interventions": [
        {
          "name": "RNS60",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Revalesio Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "18 Years to 55 Years · Male only"
      },
      "enrollment_count": 12,
      "start_date": "2011-07",
      "completion_date": "2011-09",
      "has_results": false,
      "last_update_posted_date": "2011-10-04",
      "last_synced_at": "2026-11-11T14:00:04.294Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01264783"
    },
    {
      "nct_id": "NCT05021666",
      "title": "A Phase 1, Double-blind, Randomized, Placebo-controlled, Single- and Multiple-dose Escalating Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Subjects"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "PB 718",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PegBio Co., Ltd.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 82,
      "start_date": "2020-07-29",
      "completion_date": "2022-08-12",
      "has_results": false,
      "last_update_posted_date": "2022-09-28",
      "last_synced_at": "2026-11-11T14:00:04.294Z",
      "location_count": 1,
      "location_summary": "Daytona Beach, Florida",
      "locations": [
        {
          "city": "Daytona Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05021666"
    },
    {
      "nct_id": "NCT02735603",
      "title": "Study to Evaluate the Effect of Naltrexone and Bupropion Extended-Release Combination on Cardiac Repolarization in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Heart Repolarization"
      ],
      "interventions": [
        {
          "name": "Naltrexone HCl/bupropion HCl",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Orexigen Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 84,
      "start_date": "2016-04",
      "completion_date": "2016-10",
      "has_results": false,
      "last_update_posted_date": "2016-11-01",
      "last_synced_at": "2026-11-11T14:00:04.294Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02735603"
    },
    {
      "nct_id": "NCT05447546",
      "title": "Study to Evaluate HT-6184 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Normal Healthy Subjects"
      ],
      "interventions": [
        {
          "name": "HT-6184",
          "type": "DRUG"
        },
        {
          "name": "HT-6184 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Halia Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 64,
      "start_date": "2022-06-15",
      "completion_date": "2023-07-20",
      "has_results": false,
      "last_update_posted_date": "2023-08-28",
      "last_synced_at": "2026-11-11T14:00:04.294Z",
      "location_count": 1,
      "location_summary": "Fair Lawn, New Jersey",
      "locations": [
        {
          "city": "Fair Lawn",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05447546"
    },
    {
      "nct_id": "NCT01913002",
      "title": "Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "LX4211 800 mg",
          "type": "DRUG"
        },
        {
          "name": "LX4211 2000 mg",
          "type": "DRUG"
        },
        {
          "name": "moxifloxacin 400 mg",
          "type": "DRUG"
        },
        {
          "name": "LX4211 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lexicon Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 63,
      "start_date": "2013-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-10-30",
      "last_synced_at": "2026-11-11T14:00:04.294Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01913002"
    },
    {
      "nct_id": "NCT03276728",
      "title": "Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Volunteers and Heart Failure Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Heart Failure",
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "AMG 986 IV",
          "type": "DRUG"
        },
        {
          "name": "AMG 986 PO",
          "type": "DRUG"
        },
        {
          "name": "Placebo PO",
          "type": "DRUG"
        },
        {
          "name": "Placebo IV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 182,
      "start_date": "2016-08-12",
      "completion_date": "2019-04-18",
      "has_results": true,
      "last_update_posted_date": "2022-08-08",
      "last_synced_at": "2026-11-11T14:00:04.294Z",
      "location_count": 8,
      "location_summary": "Anaheim, California • Tustin, California • Jacksonville, Florida + 5 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Tustin",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Metairie",
          "state": "Louisiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03276728"
    },
    {
      "nct_id": "NCT03922607",
      "title": "A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-157 in Healthy Volunteers and in Participants With Chronic Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "ABBV-157",
          "type": "DRUG"
        },
        {
          "name": "Placebo for ABBV-157",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 65,
      "start_date": "2019-06-11",
      "completion_date": "2021-04-13",
      "has_results": false,
      "last_update_posted_date": "2021-05-11",
      "last_synced_at": "2026-11-11T14:00:04.294Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "North Hollywood",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03922607"
    },
    {
      "nct_id": "NCT07022119",
      "title": "A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Autosomal Dominant Polycystic Kidney Disease (ADPKD)"
      ],
      "interventions": [
        {
          "name": "VX-407",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 32,
      "start_date": "2025-06-12",
      "completion_date": "2026-02-24",
      "has_results": false,
      "last_update_posted_date": "2026-03-27",
      "last_synced_at": "2026-11-11T14:00:04.294Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07022119"
    }
  ]
}